Summary  About half of all patients who experience an acute coronary syndrome (ACS) in Australia have their conditions managed non-invasively -that is, they do not undergo coronary angiography and revascularisation in hospital.
 ACS patients whose conditions are managed non-invasively may not receive the same level of evidence-based care as those who receive coronary revascularisation.
 This article reviews the optimal pharmacological management of ACS managed non-invasively.
 There is strong evidence to support the prescription of dual antiplatelet therapy (DAPT; aspirin with a P2Y 12 inhibitor). DAPT should continue for 12 months after an ACS, then aspirin should be continued indefinitely.
 Anticoagulation with warfarin or a novel oral anticoagulant may be needed if atrial fibrillation occurs; the combination with DAPT increases the risk of bleeding.
 Unless contraindicated, high-intensity statin therapy should be prescribed for all post-ACS patients irrespective of their cholesterol level. Non-statin lipid therapy has not been shown to improve outcomes.
 Use of β-adrenergic blockers is recommended in most guidelines, but the clinical trials to support this recommendation were performed more than 30 years ago, and routine long-term use may not be relevant to modern treatment, except when there is cardiac failure or left ventricular dysfunction.
 Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are also widely recommended, but the evidence for benefit is stronger when there is left ventricular dysfunction.
 Calcium-channel blockers, nitrates, antiarrhythmic drugs, digoxin and diuretics do not improve outcomes in post-ACS patients.
Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome D espite a trend towards greater use of coronary revascularisation, half of all patients who experienced an acute coronary syndrome (ACS) in Australia in 2012 had their conditions managed noninvasively -that is, they did not receive coronary angiography with subsequent coronary stenting or bypass surgery. 1 The evidence base and international guidelines for the management of patients with ACS are extensive, 2-4 but some research suggests that patients whose ACS is treated conservatively may not receive the same level of evidence-based care as those whose ACS is managed invasively. 5 This article reviews the optimal pharmacological management of non-invasively managed ACS, and briefly reviews the evidence to support the prescription of each class of drug.
Antithrombotic therapy
As coronary thrombosis is the major cause of ACS, antithrombotic treatment regimens are now routine.
Aspirin
Aspirin in a dose of 75-325 mg daily is recommended in all guidelines for all patients after an ACS, regardless of whether revascularisation has occurred. 2-4 Its low cost and high effectiveness make it an attractive agent to reduce the risk of recurrence of coronary thrombosis. In post-ACS patients, aspirin has been shown to reduce major vascular events by 25%, with an absolute risk reduction of 35 vascular events per 1000 patients treated over 2 years. 6 Prescribing levels well in excess of 95% for post-ACS patients have been reached in Australia. 1 A limitation with aspirin therapy, even in low doses, is an increase in the risk of gastrointestinal side effects. A recent meta-analysis calculated that the odds ratio for the risk of major gastrointestinal bleeding in aspirin versus non-aspirin users was 1.55 (95% CI, 1.27-1.90). 7 Observational studies suggest that bleeding complications are fewer with lower doses of aspirin, 8 but randomised allocation to low-dose (75-100 mg) versus standard-dose (101-325 mg) aspirin in combination with clopidogrel showed no differences in bleeding at 30 days. 9 Entericcoated versions of aspirin may have fewer adverse gastric effects than buffered aspirin, but it remains unclear whether it is the enteric coating or the lower dose that decreases the risk of gastric complications. 10 Co-prescribing a proton pump inhibitor (PPI) reduces the risk of gastrointestinal bleeding, but the long-term cost-effectiveness of the combination with aspirin remains doubtful. 11 P2Y 12 inhibitors and dual antiplatelet therapy Dual antiplatelet therapy (DAPT; aspirin and a P2Y 12 inhibitor drug) is now recommended for conservatively managed post-ACS patients in all guidelines. 2-4 The CURE study, conducted nearly 15 years ago, showed a clear role for DAPT in conservatively managed ACS; patients treated with DAPT (clopidogrel and aspirin) had fewer subsequent coronary events than patients treated with aspirin alone. 12 At 12 months, the CURE trial's end point of myocardial infarction or cardiovascular death was reduced by 20% (relative risk reduction, 0.80; 95% CI, 0.72-0.90; P < 0.001). This benefit came with a moderate increase in major bleeding (relative risk, 1.38; P = 0.001). All subsequent guidelines based on the CURE trial data recommend DAPT for conservatively managed ACS.
The ideal duration of DAPT after an ACS episode without percutaneous coronary intervention (PCI) remains unclear. While there are ongoing trials to examine the optimal duration of DAPT in patients treated with PCI, 13,14 the relevance of these trial results to conservative management is not clear.
International guidelines recommend the combination of clopidogrel with aspirin for 12 months, as this was the treatment period examined in the CURE trial. 2-4 Post-hoc review of the events curves in the CURE study showed that the major benefit of clopidogrel plus aspirin over aspirin alone was in the first 6 weeks after commencement of treatment, and there have been no comparative studies to evaluate shorter or longer periods of therapy. The benefits of longer-term DAPT over aspirin have not been confirmed. 15 Concerns about resistance to clopidogrel in some patients have led to extensive research into clopidogrel resistance. "Clopidogrel resistance" is more correctly defined as high on-treatment platelet reactivity and, according to some estimates, up to 30% of patients are non-responders or poor responders to clopidogrel by this criterion. 16, 17 However, recent studies have shown that dosing based on platelet responsiveness to clopidogrel is unhelpful. 18, 19 Like aspirin, clopidogrel can increase the risk of gastrointestinal bleeding, and concomitant use of PPIs with clopidogrel has been closely examined, as several observational studies suggested that PPIs may interfere with the action of clopidogrel via competition for the cytochrome P450 pathway in the gut transport of the prodrug. 20 However, a well conducted randomised trial of omeprazole showed no clinically significant interaction with clopidogrel, 21 and the most recent meta-analyses have shown that an interaction between PPIs and clopidogrel is not significant for most patients. The earlier observations of adverse effects of the combination may have been due to PPI users being older patients, who are at increased risk of adverse cardiovascular events. 22 Newer oral agents that inhibit the P2Y 12 receptor (ticagrelor, prasugrel) have recently become available. Dosages for the three agents are summarised in Box 1.
Both ticagrelor and prasugrel are more effective in reducing subsequent coronary events, but carry a higher bleeding risk than clopidogrel. Most guidelines recommend that the newer agents are preferred for most ACS (both ST-elevation myocardial infarction and non-STelevation myocardial infarction) unless the risk of bleeding is excessive. [2] [3] [4] Prasugrel was more effective than clopidogrel in the TRITON-TIMI 38 trial in reducing coronary events. 23 However, this definitive trial of prasugrel only included patients for whom the coronary anatomy was known, and a coronary angiogram may not be available for patients whose ACS is managed conservatively. Prasugrel was ineffective for conservatively managed ACS. 24 Because of bleeding risk, care is required in older patients (> 80 years), and those who weigh under 60 kg or have renal impairment.
Ticagrelor was also shown to be more effective than clopidogrel at preventing stroke, myocardial infarction or death, as demonstrated in the PLATO trial. 25 It also has an increase in overall bleeding risk, but as the trial evidence supporting its use did not require prior coronary angiography, it has the advantage as the preferred agent for initial treatment, particularly in the patient whose ACS is likely to be managed conservatively. 26 
Warfarin and new oral anticoagulants
Post-ACS vitamin K antagonists were evaluated in the 1990s and were shown to achieve a reduction in reinfarction, and are even more effective in reducing the risk of stroke but with an increased risk of bleeding. 27 Based on this experience, two of the new oral anticoagulants (NOACs) have been tested in patients who had experienced a coronary event. Rivaroxaban was shown to reduce recurrences, but at an increased risk of bleeding. 28 Apixaban did not reduce recurrent ischaemic events and caused increased bleeding. 29 Anticoagulants for atrial fibrillation after ACS Atrial fibrillation (AF) requiring an oral anticoagulant is a common comorbidity in patients with recent ACS being treated with DAPT. Patients with non-invasively managed ACS, AF and a zero CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age у 75 years, diabetes mellitus, stroke, vascular disease, age 65 to 74 years, sex) score can be managed with aspirin or DAPT. 30 However, patients with a moderate or high risk of stroke need to be considered for triple antithrombotic therapy (DAPT for their coronary disease and an anticoagulant for their AF), and this carries an increased risk of bleeding. Registry data have quantified this risk, showing that the combination of antiplatelet agents with warfarin increases the risk of bleeding by 1.50 for aspirin and by 1.84 for clopidogrel over warfarin alone. 31 There are no trials to guide therapy for patients with non-invasively managed ACS and AF, but a randomised study of participants requiring anticoagulation and anti platelet therapy after PCI demonstrated that double therapy with clopidogrel and warfarin was associated with significantly less bleeding than triple therapy with aspirin, clopidogrel and warfarin, without any increased risk of thrombotic events. 32 To date, there are no data to guide the use of the NOACs with the newer P2Y 12 inhibitors, which are becoming standard care for patients after ACS.
Lipid-modulating medications Statins
Statin therapy is an essential part of the post-ACS regimen. Meta-analyses of trials in patients who have had a coronary event have shown that subsequent coronary events can be reduced by 25%-30%, 33 with an absolute reduction of 48 major vascular events per 1000 treated for each 1 mmol/L reduction in low-density lipoprotein (LDL) cholesterol level. 34 Commencement of the statin in hospital enhances adherence over subsequent months. 35 Lower-potency statins are less effective, 36 and a high-dose 
simvastatin was associated with a higher than acceptable incidence of myopathy in a trial of post-ACS patients and should be avoided. 39 While rosuvastatin has been shown to be effective in high-risk non-ACS cohorts, there is no specific trial to support its use after ACS. The target LDL cholesterol level for post-ACS patients is below 1.8 mmol/L. 40 It remains unclear whether a patient who achieves a reduction of LDL cholesterol to target levels with 80 mg of atorvastatin should be prescribed a lowerdose statin to reduce side effects. Many patients experience side effects while taking statins, but analysis of randomised trials has shown that major side effects are equally seen in participants treated with placebo and statins, apart from a small increase in type 2 diabetes. 41 While myopathy is uncommon, symptoms of myalgia are common and quite often lead to early cessation of statin therapy.
Non-statin lipid-modulating therapies
Ezetimibe has the potential to lower LDL cholesterol levels, either alone or in conjunction with statins, 42 but to date, there are no data to demonstrate any clinical benefit. The outcome of the IMPROVE-IT trial will be awaited with interest to see if lowering LDL cholesterol levels by non-statin therapy is effective. 43 PCSK9 inhibitors have been shown to be highly effective in lowering LDL cholesterol levels among patients with hyperlipidaemia resistant to statins, and they have an acceptable safety profile, 44,45 but the relevance of this to reducing risk among patients after ACS remains to be established.
Triglyceride-lowering medications
There is no clear-cut benefit for lowering triglyceride levels in patients after ACS. Trials of gemfibrozil 46 and bezafibrate 47 have not been sufficiently persuasive to establish fibrate therapy in post-ACS patients, and a large trial with fenofibrate did not achieve its primary end point in patients with high-risk type 2 diabetes. 48 
High-density lipoprotein cholesterol-raising medications
Trials of high-density lipoprotein (HDL) cholesterol-raising drugs have been disappointing. While cholesteryl ester transfer protein inhibitors can raise HDL cholesterol levels, they have not been shown to improve outcomes. A large torcetrapib trial in patients with stable coronary heart disease demonstrated an increased mortality. 49 A large dalcetrapib study in patients with ACS showed an effective raising of HDL cholesterol levels, but no effect on outcomes. 50 A preliminary study of anacetrapib showed that it could lower LDL cholesterol levels as well as raise HDL cholesterol levels, 51 but a large outcomes study with anacetrapib is yet to be reported.
Alternative approaches to raising HDL cholesterol levels have been explored, so far without success. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy raised HDL cholesterol levels, but showed no additional benefit over statin therapy. 52 Niacin combined with the anti-flushing agent laropiprant caused an unacceptable increase in risk of myopathy in patients taking simvastatin. 53 The challenge in HDL cholesterol management may be to target the functionality of the HDL cholesterol, rather than simply the level. 54 
Other therapies Omega 3 fatty acids
Fish oil-derived omega 3 fatty acids have been shown to moderately reduce total and sudden post-ACS deaths, but it is not clear if this is by a triglyceride-lowering effect or other mechanisms. 55 β-Adrenergic blockers β-Blockers are recommended for long-term post-ACS management in most guidelines. [2] [3] [4] This is sound advice for most patients in the early post-ACS period, but the recommendation for long-term use of β-blockers is based on evidence obtained from clinical trials conducted in the 1980s. 56 At that time, the definition of ACS was based on criteria quite different from the modern definition, which is based on subtle changes in troponin. 57 In the 1980s, the definition of a myocardial infarction for a patient to be included in a post-myocardial infarction trial required major electrocardiogram changes and a doubling of cardiac enzymes. 58 When the post-infarction oral β-blocker trials were conducted, 59-61 many modern treatments, such as early intervention with PCI, the nearuniversal use of statin therapy and the widespread use of DAPT, had not been introduced to cardiology. The relevance of 30-year-old evidence derived from patients with extensive myocardial infarction to the treatment of patients in the modern era is doubtful. 62 Recent evidence has shown no benefit of β-blockers on mortality in patients with hypertension 63 or stable coronary heart disease, 64 casting further doubt on the assumption that routine, long-term use of β-blockers in stable post-ACS patients is essential. In contrast, research among patients with left ventricular (LV) dysfunction or cardiac failure after myocardial infarction shows clear evidence of benefit for β-blockers. 65, 66 
ACE inhibitors and angiotensin receptor blockers
Angiotensin-converting enzyme (ACE) inhibitors have a role in patients with cardiac failure and significant LV dysfunction. 67 The use of ACE inhibitors in the absence of post-coronary LV dysfunction has been extensively studied, and meta-analysis of clinical trials in this group of patients shows a statistically significant but modest benefit, with 10 lives saved for 1000 patients treated over 4.4 years. 68 A recent large observational registry study did not replicate the benefits of ACE inhibitors seen in clinical trials, and failed to demonstrate any improvement in survival among patients treated with ACE inhibitors. 69 Angiotensin receptor blockade as an alternative to ACE inhibition has been trialled in post-ACS patients, but the evidence base for angiotensin receptor blockers (ARBs) is not as extensive as it is for post-infarction ACE inhibitors. 70 
Aldosterone blockade
Spironolactone and eplerenone have shown benefit in patients with cardiac failure and LV dysfunction. 71, 72 MJA 201 (10) · 17 November 2014
Eplerenone is approved for authority use on the Australian Pharmaceutical Benefits Scheme for patients with heart failure with an LV ejection fraction of 40% or less occurring within 3 to 14 days after an acute myocardial infarction. If spironolactone or eplerenone are prescribed for the post-ACS patient, meticulous monitoring of potassium levels is required, particularly for patients taking concomitant ACE inhibitors. 73 
Calcium-channel blockers
Calcium-channel blockers have not been shown to benefit prognosis for the post-infarction patient, and are not recommended as part of routine management. Verapamil and diltiazem are contraindicated in post-infarction patients with LV dysfunction. 74, 75 Amlodipine has been shown to be safe in the presence of LV dysfunction. 76 
Antiarrhythmic drugs
Antiarrhythmic drugs are not recommended, as they have not been shown to improve prognosis for patients who have had a myocardial infarction. 77 
Nitrate therapy
Nitrates are indicated for patients with symptomatic angina, but do not have a role for patients without angina after myocardial infarction. 78 
Diuretics and digoxin
Diuretics are useful for symptomatic relief of cardiac failure but have not been convincingly shown to improve prognosis for patients after ACS. 79 The need for ongoing diuretic therapy should be reviewed at the time of hospital discharge, as unnecessary diuretic therapy can cause hypovolaemia and electrolyte disturbances.
Digoxin does not have a clear role except as an alternative to β-blockers for rate control of AF. 80 
Conclusions
Recommendations for optimal pharmacotherapy in the post-ACS patient are summarised in Box 2. Most patients will recover without symptoms or LV dysfunction. Patients in this category should be routinely prescribed DAPT and a high intensity statin. The DAPT should be continued for 12 months and the aspirin and statin indefinitely. All patients should be taking a β-blocker when they leave hospital, but the evidence for long-term continuation in the modern era is minimal, and further trials are needed to clarify the ideal duration of β-blocker therapy. While ACE inhibitors or ARBs are recommended in some guidelines, the evidence for their routine use in the patient free of cardiac failure or LV dysfunction is questionable.
Patients who have documented LV dysfunction after their ACS should have the same treatment as above, but in these patients the evidence for β-blockers and ACE inhibitors or ARBs is strong and they should be prescribed. The preferred β-blocker should be one of the agents shown to be effective in clinical trials of cardiac failure or LV dysfunction. There is good evidence that aldosterone antagonists are effective in patients with LV dysfunction.
Symptomatic patients with angina or dyspnoea or cardiac failure should be treated as above and have appropriate treatment for their angina or symptoms of cardiac failure. 
